4D Molecular Therapeutics (NASDAQ:FDMT) Insider Scott Bizily Sells 1,635 Shares of Stock

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) insider Scott Bizily sold 1,635 shares of the business’s stock in a transaction on Friday, October 16th. The shares were sold at an average price of $12.84, for a total value of $20,993.40. Following the completion of the sale, the insider directly owned 8,617 shares in the company, valued at approximately $110,642.28. This represents a 15.95% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Scott Bizily also recently made the following trade(s):

• On Wednesday, September 16th, Scott Bizily sold 1,635 shares of 4D Molecular Therapeutics stock. The shares were sold at an average price of $13.65, for a total value of $22,317.75.
• On Tuesday, September 1st, Scott Bizily sold 584 shares of 4D Molecular Therapeutics stock. The stock was sold at an average price of $14.00, for a total value of $8,176.00.
• On Thursday, August 13th, Scott Bizily sold 1,635 shares of 4D Molecular Therapeutics stock. The stock was sold at an average price of $12.00, for a total value of $19,620.00.
• On Monday, August 17th, Scott Bizily sold 1,635 shares of 4D Molecular Therapeutics stock. The stock was sold at an average price of $12.20, for a total value of $19,947.00.

4D Molecular Therapeutics Stock Up 6.6%

Shares of NASDAQ FDMT opened at $13.10 on Wednesday. The stock has a market cap of $723.64 million, a PE ratio of -4.98 and a beta of 2.75. The business has a fifty day moving average of $14.05 and a two-hundred day moving average of $11.57. 4D Molecular Therapeutics, Inc. has a 52-week low of $6.96 and a 52-week high of $16.93. The company has a debt-to-equity ratio of 0.05, a quick ratio of 8.03 and a current ratio of 8.03.

4D Molecular Therapeutics (NASDAQ:FDMT) last issued its earnings results on Thursday, August 13th. The company reported ($1.04) EPS for the quarter, missing the consensus estimate of ($1.02) by ($0.02). 4D Molecular Therapeutics had a negative net margin of 194.74% and a negative return on equity of 41.33%. The firm had revenue of $3.78 million during the quarter, compared to analyst estimates of $3.62 million. As a group, equities research analysts expect that 4D Molecular Therapeutics, Inc. will post -4.14 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have commented on FDMT. Cantor Fitzgerald upgraded shares of 4D Molecular Therapeutics from a “neutral” rating to an “overweight” rating and set a $20.00 price target on the stock in a research report on Monday, September 14th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research note on Thursday, October 15th. B. Riley Financial reaffirmed a “buy” rating on shares of 4D Molecular Therapeutics in a report on Monday, August 17th. The Goldman Sachs Group reiterated a “buy” rating and issued a $32.00 target price on shares of 4D Molecular Therapeutics in a research note on Thursday, August 13th. Finally, Chardan Capital cut their target price on shares of 4D Molecular Therapeutics from $26.00 to $25.00 and set a “buy” rating for the company in a research note on Tuesday, October 6th. Ten investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $28.90.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the stock. Sei Investments Co. lifted its holdings in 4D Molecular Therapeutics by 8.9% during the 1st quarter. Sei Investments Co. now owns 12,862 shares of the company’s stock worth $120,000 after buying an additional 1,050 shares in the last quarter. Toth Financial Advisory Corp bought a new position in 4D Molecular Therapeutics in the 3rd quarter valued at $29,000. Headlands Technologies LLC increased its stake in shares of 4D Molecular Therapeutics by 20.6% in the 2nd quarter. Headlands Technologies LLC now owns 19,238 shares of the company’s stock valued at $256,000 after buying an additional 3,282 shares during the period. Legal & General Group Plc acquired a new stake in shares of 4D Molecular Therapeutics in the 2nd quarter valued at $59,000. Finally, Susquehanna Fundamental Investments LLC acquired a new stake in shares of 4D Molecular Therapeutics in the 2nd quarter valued at $148,000. Institutional investors own 99.27% of the company’s stock.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc is a clinical-stage biotechnology company focused on developing gene therapies for serious diseases. The company uses its Therapeutic Vector Evolution platform to engineer adeno-associated virus (AAV) vectors designed to deliver genetic medicines to specific tissues, including the eye and lungs.

Its investigational pipeline includes 4D-150, an intravitreal gene therapy being developed for retinal diseases such as wet age-related macular degeneration and diabetic macular edema.